Gilead Accused of Propping Up Truvada by Blocking Generics (1)

Gilead Sciences Inc. was hit with a lawsuit accusing it of using “an array of anti-competitive practices” to prop up the price of its blockbuster HIV drug Truvada by delaying the rollout of competing generics.

Gilead has conspired with other drugmakers to gain and maintain “a stranglehold” on the market for lifesaving medication combinations featuring its breakthrough drug, known generically as tenofovir, which has sales exceeding $11 billion a year, according to the proposed class action. The suit was filed May 14 in California federal court by a Fraternal Order of Police pension fund.

The other companies named as defendants ...